Winona launched four supplements for women 35+ — probiotic, magnesium, multivitamin, and calcium with D3, K2 and B12. The market gap is real and the formulations are thoughtful; the phrase ‘evidence-based’ is doing heavy lifting without a single citation.
Winona has launched a four-product supplement line for women 35 and over. It’s a logical move into a genuinely underserved market — and a useful case study in how to evaluate a supplement launch, because the claims mix the well-supported with the merely plausible.
Winona, a physician-led menopause telehealth platform, has launched a four-product supplement line aimed at women 35 and over. It’s a logical business move and a genuinely underserved audience — and it’s also a useful case study in how to evaluate a supplement launch, because the claims here are a mix of the well-supported and the merely plausible.
What launched
The line consists of four products: a Pre + Pro Biotic Blend, a Magnesium Blend, a Women’s Multivitamin, and a Calcium with D3 + K2 and B12.
The formulations are more specific than most. The probiotic uses an L. plantarum OM strain paired with PreticX prebiotic fibre. The magnesium product combines nine forms, including magnesium glycinate and Sucrosomial magnesium, with vitamin B6. The calcium is paired with vitamin D3, vitamin K2 as MK-7, and B12.
Winona positions the range as addressing bone density, muscle recovery, sleep disruption and gut health, describes the products as evidence-based and free from common allergens, and presents them as usable either alone or alongside hormone replacement therapy. The company’s medical director is Dr. Cathleen Brown; co-founder Ashlie Beiter serves as VP of Marketing.
Why this market is real
Start with what’s legitimate, because it genuinely is. Perimenopause and menopause affect every woman who lives long enough, span years or decades, and have been startlingly under-researched and under-served by medicine. Women routinely report their symptoms dismissed, and many clinicians receive minimal training in menopause management.
A telehealth service built specifically around this transition addresses a real access gap. And the physiology behind the product categories isn’t invented: the decline in oestrogen at menopause genuinely accelerates bone loss, which makes bone health a legitimate priority rather than a marketing frame. Sleep disruption is one of the most commonly reported and most debilitating symptoms. Muscle mass does decline with age.
So the problems the line targets are real, well-documented, and matter to the people experiencing them.
Where to apply scrutiny
The gap in this announcement is the evidence. The products are described as evidence-based and the ingredients as clinically validated, but no specific studies are cited and no outcome data is presented. That’s standard practice in supplement marketing, and it’s exactly the point at which a reader should slow down.
“Evidence-based” is doing a lot of work in that sentence, and it can mean several different things:
Well-supported: Calcium and vitamin D for bone health in postmenopausal women is among the better-established supplement uses, particularly for women with inadequate dietary intake. Vitamin D deficiency is genuinely common. This is the strongest claim in the range.
Reasonable but softer: Magnesium for sleep has plausible mechanisms and some supportive trials, but the evidence is far weaker than the confidence of the marketing implies — and it applies most to people who are actually deficient. Magnesium glycinate is a sensible, well-absorbed form; combining nine forms in one product is a formulation choice with more marketing appeal than demonstrated advantage.
Promising but unsettled: Probiotics are an area of active research where strain-specific effects are real but frequently overstated. Naming a specific strain is a point in the product’s favour — effects don’t generalise across strains — but a named strain is not the same as demonstrated benefit for menopausal symptoms.
Also worth noting: in the United States, supplements are regulated as food rather than as drugs. They do not require pre-market approval for efficacy, and the manufacturer is responsible for safety and labelling accuracy. A physician-led brand is a meaningful signal of care, but it isn’t a regulatory guarantee.
The structural question
There is an inherent tension worth naming when a telehealth provider sells supplements to its own patients. The clinician recommending a product and the company profiting from it are the same entity.
This isn’t unique to Winona — it’s the model across most of direct-to-consumer telehealth, and vertical integration has real advantages, including formulation control and continuity of care. But it does mean the recommendation isn’t independent, and that’s a reasonable thing for a patient to factor in.
The most useful framing for a reader: supplements are best understood as filling documented gaps, not as a general-purpose intervention. The highest-value step isn’t choosing a brand — it’s finding out, through testing and an honest look at your diet, whether you’re actually short of vitamin D, calcium, B12 or magnesium. If you are, correcting that is worthwhile. If you aren’t, a well-formulated supplement mostly produces expensive urine.
The read
A menopause-focused telehealth company extending into supplements is a sensible move into a market that has been genuinely neglected, and the formulations show more thought than the category average — specific strains, well-absorbed magnesium forms, vitamin K2 alongside calcium and D3.
Hold the marketing language to a normal standard anyway. “Evidence-based” without citations is a claim, not a demonstration, and the strength of support varies substantially across the four products. The bone-health formulation rests on the firmest ground; the sleep and gut-health claims rest on softer ground than the confidence suggests.
And supplements are not a substitute for the conversation about menopause management — including HRT, which remains the most effective treatment for many symptoms and which the company itself frames these products as complementing rather than replacing. That framing is correct, and it’s the part most worth carrying away.
Reporting on a company product launch, as covered on 22 July 2026. Product claims are the manufacturer’s and have not been independently verified; no specific studies were cited in the announcement. Dietary supplements are not evaluated by the FDA for efficacy and are not intended to diagnose, treat, cure or prevent any disease. This is general information, not medical advice — consult a qualified clinician about menopause management and before starting any supplement. Source.
